Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free MTEX Stock Alerts

Mannatech (MTEX) Competitors

Mannatech logo
$5.16 0.00 (0.00%)
As of 07/2/2026 04:00 PM Eastern
Compare

MTEX vs. MIRA, GOSS, GRCE, ACTU, and GRML

Should you buy Mannatech stock or one of its competitors? MarketBeat compares Mannatech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mannatech include MIRA Pharmaceuticals (MIRA), Gossamer Bio (GOSS), Grace Therapeutics (GRCE), Actuate Therapeutics (ACTU), and Greenland Mines Ltd. Common Stock (GRML). These companies are all part of the "pharmaceutical products" industry.

How does Mannatech compare to MIRA Pharmaceuticals?

Mannatech (NASDAQ:MTEX) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

MIRA Pharmaceuticals has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. MIRA Pharmaceuticals' return on equity of -140.82% beat Mannatech's return on equity.

Company Net Margins Return on Equity Return on Assets
Mannatech-11.97% -2,383.34% -40.24%
MIRA Pharmaceuticals N/A -140.82%-135.01%

In the previous week, Mannatech had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 1 mentions for Mannatech and 0 mentions for MIRA Pharmaceuticals. Mannatech's average media sentiment score of 0.00 equaled MIRA Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Mannatech Neutral
MIRA Pharmaceuticals Neutral

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MIRA Pharmaceuticals has lower revenue, but higher earnings than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mannatech$106.39M0.09-$15.21M-$6.71N/A
MIRA PharmaceuticalsN/AN/A-$10.44M-$1.30N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mannatech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
MIRA Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Mannatech has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

Summary

MIRA Pharmaceuticals beats Mannatech on 9 of the 13 factors compared between the two stocks.

How does Mannatech compare to Gossamer Bio?

Mannatech (NASDAQ:MTEX) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

Mannatech has higher revenue and earnings than Gossamer Bio. Mannatech is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mannatech$106.39M0.09-$15.21M-$6.71N/A
Gossamer Bio$48.47M0.84-$170.37M-$0.79N/A

Gossamer Bio has a consensus target price of $4.50, indicating a potential upside of 2,498.15%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Mannatech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mannatech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Gossamer Bio
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.20

13.0% of Mannatech shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 41.5% of Mannatech shares are held by insiders. Comparatively, 3.7% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Mannatech has a net margin of -11.97% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Mannatech's return on equity.

Company Net Margins Return on Equity Return on Assets
Mannatech-11.97% -2,383.34% -40.24%
Gossamer Bio -324.82%N/A -96.10%

In the previous week, Gossamer Bio had 2 more articles in the media than Mannatech. MarketBeat recorded 3 mentions for Gossamer Bio and 1 mentions for Mannatech. Gossamer Bio's average media sentiment score of 0.24 beat Mannatech's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mannatech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gossamer Bio
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Mannatech has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

Summary

Gossamer Bio beats Mannatech on 11 of the 16 factors compared between the two stocks.

How does Mannatech compare to Grace Therapeutics?

Mannatech (NASDAQ:MTEX) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Grace Therapeutics has a consensus price target of $6.00, indicating a potential upside of 153.16%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Grace Therapeutics is more favorable than Mannatech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mannatech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Grace Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Mannatech has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

Grace Therapeutics has lower revenue, but higher earnings than Mannatech. Grace Therapeutics is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mannatech$106.39M0.09-$15.21M-$6.71N/A
Grace TherapeuticsN/AN/A-$7.79M-$0.48N/A

Grace Therapeutics has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Grace Therapeutics' return on equity of -14.45% beat Mannatech's return on equity.

Company Net Margins Return on Equity Return on Assets
Mannatech-11.97% -2,383.34% -40.24%
Grace Therapeutics N/A -14.45%-13.58%

In the previous week, Mannatech had 1 more articles in the media than Grace Therapeutics. MarketBeat recorded 1 mentions for Mannatech and 0 mentions for Grace Therapeutics. Mannatech's average media sentiment score of 0.00 equaled Grace Therapeutics'average media sentiment score.

Company Overall Sentiment
Mannatech Neutral
Grace Therapeutics Neutral

13.0% of Mannatech shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 41.5% of Mannatech shares are held by company insiders. Comparatively, 11.1% of Grace Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Grace Therapeutics beats Mannatech on 8 of the 14 factors compared between the two stocks.

How does Mannatech compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Mannatech has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actuate TherapeuticsN/AN/A-$22.23M-$0.97N/A
Mannatech$106.39M0.09-$15.21M-$6.71N/A

Actuate Therapeutics has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Actuate Therapeutics' return on equity of -430.93% beat Mannatech's return on equity.

Company Net Margins Return on Equity Return on Assets
Actuate TherapeuticsN/A -430.93% -180.86%
Mannatech -11.97%-2,383.34%-40.24%

In the previous week, Mannatech had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 1 mentions for Mannatech and 0 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.00 equaled Mannatech'saverage media sentiment score.

Company Overall Sentiment
Actuate Therapeutics Neutral
Mannatech Neutral

Actuate Therapeutics presently has a consensus target price of $17.50, indicating a potential upside of 1,051.32%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Actuate Therapeutics is more favorable than Mannatech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actuate Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Mannatech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Actuate Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Mannatech has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

13.0% of Mannatech shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 41.5% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Actuate Therapeutics and Mannatech tied by winning 7 of the 14 factors compared between the two stocks.

How does Mannatech compare to Greenland Mines Ltd. Common Stock?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

In the previous week, Greenland Mines Ltd. Common Stock had 1 more articles in the media than Mannatech. MarketBeat recorded 2 mentions for Greenland Mines Ltd. Common Stock and 1 mentions for Mannatech. Greenland Mines Ltd. Common Stock's average media sentiment score of 0.30 beat Mannatech's score of 0.00 indicating that Greenland Mines Ltd. Common Stock is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Greenland Mines Ltd. Common Stock
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mannatech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Greenland Mines Ltd. Common Stock has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Greenland Mines Ltd. Common Stock's return on equity of -109.40% beat Mannatech's return on equity.

Company Net Margins Return on Equity Return on Assets
Greenland Mines Ltd. Common StockN/A -109.40% -98.80%
Mannatech -11.97%-2,383.34%-40.24%

Greenland Mines Ltd. Common Stock has higher earnings, but lower revenue than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Greenland Mines Ltd. Common Stock, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Greenland Mines Ltd. Common StockN/AN/A-$10.55M-$0.32N/A
Mannatech$106.39M0.09-$15.21M-$6.71N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Greenland Mines Ltd. Common Stock
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Mannatech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 11.3% of Greenland Mines Ltd. Common Stock shares are owned by company insiders. Comparatively, 41.5% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Greenland Mines Ltd. Common Stock has a beta of 7.05, indicating that its share price is 605% more volatile than the broader market. Comparatively, Mannatech has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

Summary

Greenland Mines Ltd. Common Stock beats Mannatech on 9 of the 12 factors compared between the two stocks.

Get Mannatech News Delivered to You Automatically

Sign up to receive the latest news and ratings for MTEX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MTEX vs. The Competition

Export
MetricMannatechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$9.96M$3.10B$7.16B$12.48B
Dividend YieldN/A2.05%2.66%6.52%
P/E Ratio-0.7720.0628.0224.70
Price / Sales0.09360.33540.3799.49
Price / CashN/A57.4949.2657.09
Price / Book-1.884.3210.966.46
Net Income-$15.21M$64.45M$3.57B$337.01M
7 Day Performance1.78%2.97%2.12%1.69%
1 Month Performance-9.47%6.83%5.25%3.81%
1 Year Performance-44.52%29.07%33.29%23.90%

Mannatech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MTEX
Mannatech
1.1468 of 5 stars		$5.16
flat		N/A-44.5%$9.96M$106.39MN/A250
MIRA
MIRA Pharmaceuticals
0.7106 of 5 stars		$0.95
-0.3%		N/A-19.6%$39.77MN/AN/A2
GOSS
Gossamer Bio
3.0293 of 5 stars		$0.17
+1.8%		$4.50
+2,594.6%		-85.9%$39.19M$55.54MN/A180
GRCE
Grace Therapeutics
2.0221 of 5 stars		$2.28
-1.1%		$6.00
+163.7%		-24.3%$37.01MN/AN/AN/A
ACTU
Actuate Therapeutics
1.8008 of 5 stars		$1.52
-3.9%		$17.50
+1,052.1%		-76.7%$36.34MN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MTEX) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel